基于药物基因组学定制髋膝关节置换术后镇痛药物的前瞻性随机研究
该前瞻性随机双盲研究对107例全关节置换患者术前采集颊拭子,检测16个基因变异,将患者随机分为对照组和定制组。对照组常规处方羟考酮、曲马多和塞来昔布,定制组对代谢异常者换用氢吗啡酮或美洛昔康。结果显示定制组10天平均疼痛评分4.2 vs 3.1(P<.05),阿片类药物消耗量162.6 mg vs 86.7 mg(P=.126),作者认为基于药物基因组学定制术后镇痛可降低疼痛评分并减少镇痛药消耗。
要点
- 107例患者中24例(22.4%)存在标准镇痛方案的基因变异。
- 定制组10天平均疼痛评分3.1 vs 对照组4.2(P<.05)。
- 有基因变异者定制组10天MME消耗86.7 mg vs 对照组162.6 mg(P=.126)。
核心结论
- 作者认为,基于药物基因组检测定制术后镇痛处方可使患者达到更低的疼痛水平,同时减少镇痛药物消耗。
研究设计与样本
- 前瞻性随机双盲研究,术前采集107例全关节置换患者的颊拭子,检测16个基因(包括CYP2D6、CYP2C9、OPRM1、CYP1A2)的变异,随机分为对照组和定制组。
主要发现
- 107例患者中24例(22.4%)存在标准术后镇痛方案相关药物的基因变异。
- 有基因变异的对照组患者10天消耗MME为162.6 mg,定制组同期仅消耗86.7 MME(P=.126)。
- 对照组10天平均疼痛评分为4.2,定制组仅为3.1(P<.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study is to determine whether pharmacogenetic testing could be used to effectively customize postoperative pain medicine following total joint replacement. METHODS: Buccal swabs were collected preoperatively from 107 patients. Pharmacogenetic testing was performed for genetic variants on a panel of 16 genes, including CYP2D6, CYP2C9, OPRM1, and CYP1A2, which affect the pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs and many opioids. Patients were randomized to a control group or custom group and blinded to their group. The control group was prescribed oxycodone, tramadol, and celecoxib for postoperative pain management. If any of those were not normally metabolized, they were not prescribed to the patients in the custom group, who were given an alternative drug (hydromorphone for narcotics, meloxicam for non-steroidal anti-inflammatory drugs). Patients recorded their pain level (0-10 numeric scale) and all medications taken daily for the first 10 days following surgery. Medication was converted to milligram morphine equivalents (MMEs). RESULTS: Genetic variations to medications in our standard postoperative pain management protocol occurred in 24 of the 107 patients (22.4%). The 10-day MME consumed by patients in the control group with genetic variants was 162.6 mg. Patients with variants who had custom postoperative medication consumed only 86.7 MME in the same timeframe (P = .126). The control group demonstrated a higher 10-day average pain level of 4.2 vs the custom group pain level of only 3.1 (P < .05). CONCLUSION: With custom postoperative pain prescriptions based on pharmacogenetic testing, patients were able to achieve lower pain levels while reducing the consumption of pain medication.
引用
- Hamilton WG, Gargiulo JM, Reynolds TR, et al. Prospective Randomized Study Using Pharmacogenetics to Customize Postoperative Pain Medication Following Hip and Knee Arthroplasty. J Arthroplasty. 2022. PMID: 35279338. doi:10.1016/j.arth.2022.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。